Moreover, recently, a new generation of ICIs, namely, the inhibitors of the lymphocyte-activation gene 3 (LAG-3), applied in combination with PD-1 inhibitors, has yielded very promising results and has been added in the therapeutic armamentarium for patients with metastatic or unresectable melanoma [7]. This evidence concerns the gene LAG3 and melanoma.